CSIMarket Company Name, Ticker, Competitors, else..
 
Imunon Inc   (NASDAQ: IMNN)
Other Ticker:  
 
 
Price: $0.8700 $-0.02 -2.247%
Day's High: $0.89 Week Perf: -1.47 %
Day's Low: $ 0.86 30 Day Perf: -3.33 %
Volume (M): 6 52 Wk High: $ 3.65
Volume (M$): $ 5 52 Wk Avg: $1.10
Open: $0.86 52 Wk Low: $0.64



 Market Capitalization (Millions $) 13
 Shares Outstanding (Millions) 14
 Employees 19
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -19
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Imunon Inc
Imunon Inc is a bio-technology company specializing in the development of novel immunotherapeutic treatments. The company focuses on harnessing the power of the immune system to combat various diseases, including cancer and autoimmune disorders. Imunon Inc conducts research and development to create innovative therapies that improve patient outcomes and quality of life. The company's mission is to revolutionize the field of immunotherapy by delivering safe and effective treatments that address significant unmet medical needs.


   Company Address: 997 Lenox Drive Lawrenceville 8648 NJ
   Company Phone Number: 896-9100   Stock Exchange / Ticker: NASDAQ IMNN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY        0.3% 
JNJ        0.79% 
LLY   -0.12%    
MRK        1.51% 
PFE        2.39% 
REGN   -3.08%    
• View Complete Report
   



Imunon Inc

Imunon Inc's Stock Soars as Pharmaceutical Industry Earnings Revealed

Imunon Inc, a company within the Major Pharmaceutical Preparations industry, has seen a significant increase in its stock value over the past five trading days. The stock gained 10.22%, extending its year to date gains to an impressive 122.03%. Currently trading on the NASDAQ, Imunon Inc stock is performing exceptionally well, sitting at 43.5% above its 52-week average.
During the January to March 31 reporting cycle in 2024, many companies across various industries have been disclosing their earnings. Imunon Inc recently announced an operating deficit of $-5.011446 million for the most recent fiscal period. This result is a promising revelation compared to the operating deficit in Q1 of 2023, which was $-5.68445 million.
Imunon Inc

Imunon Inc Shows Resilience in Revenue Despite Mixed Financial Report

Imunon Inc, a pharmaceutical company, recently released its financial report for the fourth quarter of 2023, which showed both positive and negative trends. The company reported a decrease in its net loss per share, dropping from $-1.52 in the same period a year prior to $-0.42. However, the deficit grew from $-0.37 per share in the preceding reporting period. Despite this, Imunon Inc was able to reduce its net deficit from $-13.233 million to $-4.888 million compared to the same period a year ago.
On the revenue side, Imunon Inc saw no change, with revenue remaining at $0.00 million from the previous year. The company also reported a shortfall of $-19.51 million for the financial 12 months of 2023. Additionally, Imunon Inc's deficit per share for the fiscal year 2023 decreased to $-2.16 from $-5.03 in the preceding year, but there was no significant change in revenue from the year prior.
Imunon Inc

Imunon Inc. Battles Financial Woes: Investors Remain Skeptical Despite Slight Improvement in Losses

Imunon Inc: A Bearish Outlook for Investors
The financial results for Imunon Inc, as reported for the time-frame ending September 30, 2023, raise some concerns for investors. With a loss per share of $-0.37, the company has seen a slight improvement compared to the loss per share of $-0.87 reported a year ago. However, this improvement is not significant enough to instill confidence in the company's financial performance.
Moreover, the EPS has only marginally improved from $-0.61 per share in the preceding reporting season. This indicates that the company's profitability has not shown much progress, and it remains to be seen if Imunon Inc can sustain positive growth in the long run.
Imunon Inc

Record Net Losses and Drastic Ranking Drop in Healthcare Sector

Imunon Inc records a net loss of $-24 million for the fiscal year ending in the first quarter of 2023. Despite this, within the healthcare sector, 484 other companies recorded a higher return on assets. This negative trend is reflected in Imunon's ranking, which has fallen drastically compared to the second quarter of 2022.
For the fiscal year ending in March 2023, Imunon experienced a significant increase in losses, with $-0.68 per share compared to $-0.06 per share the year before. However, there was an improvement in income per share, which rose from $-0.87 to $0.00 million. Unfortunately, revenue remained stagnant at $0.00 million, marking a decline from $0.13 million last year.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com